Perrigo’s New Papa: CEO Brings Product Development Know-How To Post
This article was originally published in The Tan Sheet
Joseph Papa brings 30 years of experience in healthcare and specialty generic pharmaceutical industries to his new position as president and CEO of Perrigo, the private-label manufacturer announced Sept. 11
You may also be interested in...
Pursuit of private-label omeprazole for a possible 2007 launch fits Perrigo's ongoing strategy of focusing on new products to drive sales growth
Perrigo generic Nicorette approval: The Allegan, Mich.-based generics manufacturer has received FDA approval to market store-brand versions of GlaxoSmithKline's Nicorette Fresh Mint (coated nicotine polacrilex gum 2 mg and 4 mg) smoking cessation gum, the firm announces June 14. Retail sales for GSK's Fresh Mint gum were approximately $100 mil. for the past 12 months. Perrigo currently produces generic versions of GSK's uncoated NRT gum products as well as nicotine polacrilex lozenges equivalent to GSK's Commit product. "We are pleased with this important addition to our store brand nicotine replacement therapy product offerings, even though some sales may come at the expense of our uncoated gum products," Executive VP and General Manager - Perrigo Consumer Healthcare John Hendrickson states. The product will begin shipping to food, drug, mass market, dollar store and club store retailers in the fourth quarter and will cost approximately 25% to 40% less than the branded, the firm says...
Reformulating pseudoephedrine products has posed a greater challenge than expected for a number of firms, as passage of a federal bill restricting sale of the ingredient looms